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Background: Burkitt lymphoma (BL) is the most common
form of non-Hodgkin lymphoma that occurs in children and
adolescents (Miles/Cairo, BJH, 2012). The prognosis for pa-
tients with relapsed/resistant BL is very dismal (Cairo, et al, J
Clin Oncol, 2012). We have previously reported that
expanded Peripheral Blood Natural Killer (exPBNK) Cells
electroporated with anti-CD20 Chimeric Antigen Receptor
(CAR) mRNA have signiﬁcant cytotoxicity against CD20+
Rituximab (Rx) sensitive and resistant BL in vitro (Chu/Cairo,
et al, ASH, 2012).
Objective: To examine the anti-tumor effect of anti-CD20
chimeric antigen receptor (CAR+) modiﬁed exPBNK against
CD20+ Rx sensitive and resistant BL in vivo using xenografted
NSG mice.
Methods: anti-CD20 CAR mRNA was nucleofected into
CD56+CD3- exPBNK and CAR expression was detected by
ﬂow cytometry as described (Chu & Cairo, et al, ASH, 2012).
5x105 Rx sensitive (Raji) or resistant (Raji-2R) cells
expressing luciferase was i.p. or s.c. injected into the 6 wks-
old NSG mice. The engraftment and progression were eval-
uated using the Xenogen IVIS200 system after injection of
D-luciferin. After the engraftment was veriﬁed, 5x106 CAR
exPBNK, MOCK exPBNK (no CAR mRNA electroporation) or
medium only was i.p. injected to each mouse once aweek for
3 weeks. The cumulative luciferase signals and tumor size
were measured weekly to indicate the tumor growth,
dissemination and progression. The results with a P value <
0.05 were deemed statistically signiﬁcant.
Results: In the Raji xenografted mice model, after the third
injection, the luciferase signals measured in the CAR
exPBNK treated Raji mice were signiﬁcantly reduced than
that in the control mice (P¼0.0087) and the mock exPBNK
treated mice (P¼0.0128) (Fig.1A). And the CAR exPBNK
treated Raji mice had signiﬁcantly extended survival time
with median 40 days compared to the untreated mice (29
days, P<0.001) and the mock exPBNK treated mice (30 days,
P<0.001) (Fig.1B).
Similarly, in the Raji-2R xenograftedmicemodel, after the
third injection, the luciferase signals were also signiﬁcantly
reduced in the CAR exPBNK treated Raji-2R mice compared
to the mock exPBNK treated mice (P<0.01). And the tumor
size measured in the CAR exPBNK treated Raji-2R mice was
signiﬁcantly smaller than that in the control mice (P¼0.0175)and the mock exPBNK treated mice (P¼0.0122) (Fig.2A). The
CAR exPBNK treated Raji-2R mice had signiﬁcantly extended
survival time with median 24 days compared to the un-
treated mice (18 days, P<0.001) and the mock exPBNK
treated mice (22 days, P<0.05) (Fig.2B).
Conclusion: Multiple injections of anti-CD20 CAR mRNA
electroporated exPBNK cells can signiﬁcantly mediate Rx
sensitive and resistant BL tumor regression and extend the
survival of BL xenografted mice. These results indicate
therapeutic potential of multiple injections of CAR mRNA
modiﬁed exPBNK cells against relapsed/resistant BL in
patients.
